- Home
- CLCO vs FULC Comparison
CLCO vs FULC Comparison
Compare CLCO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLCO | FULC |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.6M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLCO | FULC |
|---|---|---|
| Price | $9.81 | $14.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 167.4K | ★ 2.2M |
| Earning Date | 11-20-2025 | 10-29-2025 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $327,762,000.00 | N/A |
| Revenue This Year | $5.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.78 | ★ N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $4.51 | $2.32 |
| 52 Week High | $9.86 | $15.74 |
Technical Indicators
Market Signals| Indicator | CLCO | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 63.08 | 72.49 |
| Support Level | $9.74 | $8.63 |
| Resistance Level | $9.83 | $15.74 |
| Average True Range (ATR) | 0.07 | 1.23 |
| MACD | -0.02 | 0.26 |
| Stochastic Oscillator | 85.29 | 82.56 |
Price Performance
Historical ComparisonAbout CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.